Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats

Bone

Volumn 46, Issue 5, 2010, Pages 1267-1274

  Shahnazari, Mohammad ^a   Yao, Wei ^a   Dai, WeiWei ^a   Wang, Bob ^a   Ionova Martin, Sophi S ^b,c   Ritchie, Robert O ^b,c   Heeren, Daniel ^a   Burghardt, Andrew J ^d   Nicolella, Daniel P ^e   Kimiecik, Michael G ^b,c   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c Lawrence Berkeley National Laboratory   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SOUTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Bisphosphonate; Bisphosphonate dose; Bone mineralization; Material properties; Structural properties

Indexed keywords

IBANDRONIC ACID; RISEDRONIC ACID;

AGING; ANIMAL EXPERIMENT; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE STRUCTURE; COMPRESSION; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FEMUR; FEMUR SHAFT; FINITE ELEMENT ANALYSIS; FISCHER 344 RAT; LOADING TEST; LUMBAR VERTEBRA; MECHANICAL STRESS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOPENIA; RAT; RIGIDITY; TIBIA; TRABECULAR BONE; VERTEBRA BODY; YOUNG MODULUS;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; COMPRESSIVE STRENGTH; DIPHOSPHONATES; FEMALE; FINITE ELEMENT ANALYSIS; LUMBAR VERTEBRAE; OVARIECTOMY; RATS; RATS, INBRED F344;

EID: 77951256024     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.11.019     Document Type: Article

References (63)

1. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004, 350(12):1189-1199.
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541.
3. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 1998, 280(24):2077-2082.
4. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J. Bone Miner. Res. 2003, 18(3):512-520.
5. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 2002, 23(4):570-578.
6. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint. Surg. Br. 2007, 89(3):349-353.
7. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39(2):224-231.
8. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 2000, 15(4):613-620.
9. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 2007, 22(11):1759-1765.
10. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 2007, 356(18):1809-1822.
11. Lewiecki E.M., Keaveny T.M., Kopperdahl D.L., Genant H.K., Engelke K., Fuerst T., et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2009, 94(1):171-180.
12. Hooper M., Faustino A., Reid I.R., Hosking D., Gilchrist N.L., Selby P., et al. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. Osteoporos Int. 2009, 20(1):141-150.
13. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 1995, 333(22):1437-1443.
14. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Jama 1999, 282(14):1344-1352.
15. Turner C.H. Yield behavior of bovine cancellous Bone. J. Biomech. Eng. 1989, 111(3):256-260.
16. Hvid I., Bentzen S.M., Linde F., Mosekilde L., Pongsoipetch B. X-ray quantitative computed tomography: the relations to physical properties of proximal tibial trabecular bone specimens. J. Biomech. 1989, 22(8-9):837-844.
17. Keaveny T.M., Wachtel E.F., Ford C.M., Hayes W.C. Differences between the tensile and compressive strengths of bovine tibial trabecular bone depend on modulus. J. Biomech. 1994, 27(9):1137-1146.
18. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 1996, 312(7041):1254-1259.
19. Chesnut C.H., Rosen C.J. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J. Bone Miner. Res. 2001, 16(12):2163-2172.
20. Cheng Z., Yao W., Zimmermann E.A., Busse C., Ritchie R.O., Lane N.E. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J. Bone Miner. Res. 2009, 24(2):209-220.
21. Migliorati C.A., Schubert M.M., Peterson D.E. Bisphosphonate osteonecrosis (BON): unanswered questions and research possibilities. Rev. Recent. Clin. Trials 2009, 4(2):99-109.
22. Delmas P.D., Benhamou C.L., Man Z., Tlustochowicz W., Matzkin E., Eusebio R., et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008, 19(7):1039-1045.
23. Delmas P.D., McClung M.R., Zanchetta J.R., Racewicz A., Roux C., Benhamou C.L., et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008, 42(1):36-42.
24. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J. Bone Miner. Res. 2008, 23(10):1689-1697.
25. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32(1):45-55.
26. Verhulp E., van Rietbergen B., Muller R., Huiskes R. Indirect determination of trabecular bone effective tissue failure properties using micro-finite element simulations. J. Biomech. 2008, 41(7):1479-1485.
27. Borah B., Ritman E.L., Dufresne T.E., Jorgensen S.M., Liu S., Sacha J., et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37(1):1-9.
28. Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006, 39(2):345-352.
29. Yao W., Cheng Z., Pham A., Busse C., Zimmermann E.A., Ritchie R.O., et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 2008, 58(11):3485-3497.
30. Parfitt A.M. Bone histomorphometry: proposed system for standardization of nomenclature, symbols, and units. Calcif. Tissue Int. 1988, 42(5):284-286.
31. Ritchie R.O., Koester K.J., Ionova S., Yao W., Lane N.E., Ager J.W. Measurement of the toughness of bone: a tutorial with special reference to small animal studies. Bone 2008, 43(5):798-812.
32. Akhter M.P., Cullen D.M., Gong G., Recker R.R. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 2001, 29(2):121-125.
33. Zhang J., Niebur G.L., Ovaert T.C. Mechanical property determination of bone through nano- and micro-indentation testing and finite element simulation. J. Biomech. 2008, 41(2):267-275.
34. Hoffler C.E., Guo X.E., Zysset P.K., Goldstein S.A. An application of nanoindentation technique to measure bone tissue Lamellae properties. J. Biomech. Eng. 2005, 127(7):1046-1053.
35. He L.H., Fujisawa N., Swain M.V. Elastic modulus and stress-strain response of human enamel by nano-indentation. Biomaterials 2006, 27(24):4388-4398.
36. Balooch G., Marshall G.W., Marshall S.J., Warren O.L., Asif S.A., Balooch M. Evaluation of a new modulus mapping technique to investigate microstructural features of human teeth. J. Biomech. 2004, 37(8):1223-1232.
37. Ladd A.J., Kinney J.H., Haupt D.L., Goldstein S.A. Finite-element modeling of trabecular bone: comparison with mechanical testing and determination of tissue modulus. J. Orthop. Res. 1998, 16(5):622-628.
38. van Rietbergen B., Weinans H., Huiskes R., Odgaard A. A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models. J. Biomech. 1995, 28(1):69-81.
39. Ulrich D., Rietbergen B., Laib A., Ruegsegger P. Mechanical analysis of bone and its microarchitecture based on in vivo voxel images. Technol. Health Care 1998, 6(5-6):421-427.
40. Eswaran S.K., Gupta A., Adams M.F., Keaveny T.M. Cortical and trabecular load sharing in the human vertebral body. J. Bone Miner. Res. 2006, 21(2):307-314.
41. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. 2009, 20(6):887-894.
42. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14(4):595-608.
43. Bauss F., Lalla S., Endele R., Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol. 2002, 29(10):2200-2208.
44. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma 2008, 22(5):346-350.
45. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 2009, 24(6):1095-1102.
46. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South. Med. J. 2001, 94(6):569-573.
47. Compston J. Bone quality: what is it and how is it measured?. Arq. Bras. Endocrinol. Metabol. 2006, 50(4):579-585.
48. Riggs B.L., Melton L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J. Bone Miner. Res. 2002, 17(1):11-14.
49. Currey J.D. The mechanical consequences of variation in the mineral content of Bone. J. Biomech. 1969, 2(1):1-11.
50. Meunier P.J., Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997, 21(5):373-377.
51. Currey J.D. Effects of differences in mineralization on the mechanical properties of Bone. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1984, 304(1121):509-518.
52. Hernandez C.J. How can bone turnover modify bone strength independent of bone mass?. Bone 2008, 42(6):1014-1020.
53. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27(5):687-694.
54. Roschger P., Gupta H.S., Berzlanovich A., Ittner G., Dempster D.W., Fratzl P., et al. Constant mineralization density distribution in cancellous human Bone. Bone 2003, 32(3):316-323.
55. Ensrud K.E., Black D.M., Palermo L., Bauer D.C., Barrett-Connor E., Quandt S.A., et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch. Intern. Med. 1997, 157(22):2617-2624.
56. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 2001, 16(1):157-165.
57. Turner C.H. Determinants of skeletal fragility and bone quality. J. Musculoskelet. Neuronal. Interact. 2002, 2(6):527-528.
58. Currey J.D., Pitchford J.W., Baxter P.D. Variability of the mechanical properties of bone, and its evolutionary consequences. J. R. Soc. Interface 2007, 4(12):127-135.
59. Rice J.C., Cowin S.C., Bowman J.A. On the dependence of the elasticity and strength of cancellous bone on apparent density. J. Biomech. 1988, 21(2):155-168.
60. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 2008, 358(12):1304-1306.
61. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab. 2008, 93(8):2948-2952.
62. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000, 11(1):83-91.
63. Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004, 15(10):792-798.